DRMA Stock Price & Analysis — Dermata Therapeutics Inc (Healthcare >> Biotechnology)
DRMA FAQ
What is DRMA's ROE?
Dermata Therapeutics Inc reports a Return on Equity (ROE) of -110.75%.
What is DRMA's dividend yield?
Dermata Therapeutics Inc offers a dividend yield of 0.00%.
What is DRMA's Quality Score?
Our AI rates DRMA's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy DRMA?
Our AI Timing Score for DRMA is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does DRMA belong to?
Dermata Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
DRMA AI Analysis Summary
Our AI summary for DRMA: Dermata Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -110.75%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.17
Price
0.07
(6.36%)
Day Change
|
|
|---|
DRMA, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.17 |
| PBV / Sector |
0.69 / 44,105.10
GREAT
|
| Earning Per Share | -1.88 |
| PE / Sector |
N/A / 19.37
|
| PEG or PE/Growth / Sector |
N/A / 1.06
|
| Average 1M Daily Value |
0.08 M
GREAT
|
| Average 1W Daily Value |
0.10 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-06 07:59:53 |
| Symbol | DRMA |
| Name | DERMATA THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 4.02 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4.42 / 9,702.21 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3525 Del Mar Heights Rd., San Diego, CA, United States, 92130
Phone: 858 800 2543
Website: https://www.dermatarx.com
Sector: Healthcare >> Biotechnology
Description: Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap
Google